Direct Oral Anticoagulant Use in Valvular Heart Disease
Key result
This review summarizes current clinical and scientific data pertaining to the safety and efficacy of direct oral anticoagulant use in patients with atrial fibrillation and valvular heart disease.
Why the study?
Are direct oral anticoagulants safe and effective in patients with atrial fibrillation and concomitant valvular heart disease?
Population
Patients with atrial fibrillation and concomitant valvular heart disease
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
DOACs' role in AF with VHD remains unclear; leaves open need for dedicated trials across specific native valve lesions.
Structured PICO
Are direct oral anticoagulants safe and effective in patients with atrial fibrillation and concomitant valvular heart disease?
P
Population
Patients with atrial fibrillation and concomitant valvular heart disease (primarily native aortic valve disease, tricuspid valve disease, or mitral regurgitation)
I
Intervention
Direct oral anticoagulants (DOACs)
O
Outcome
Safety and efficacy
This review summarizes the current clinical and scientific data pertaining to the safety and efficacy of DOAC use in patients with atrial fibrillation and valvular heart disease.
Limitations
- Limited data exist on the role of DOACs in patients with rheumatic mitral stenosis, mechanical heart valves, and mitral valve repair.
Cite This Study
Anderson et al. (2018) conducted a review in Atrial fibrillation and concomitant valvular heart disease. Direct oral anticoagulants (DOACs) was evaluated. This review summarizes current clinical and scientific data pertaining to the safety and efficacy of direct oral anticoagulant use in patients with atrial fibrillation and valvular heart disease.